Skip to content

Whole-Body Vibration for Functional Constipation

Whole-Body Vibration for Functional Constipation: A Single-Center, Single-Blinded, Randomized, Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01609608
Enrollment
26
Registered
2012-06-01
Start date
2009-10-31
Completion date
2010-11-30
Last updated
2012-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation

Brief summary

1. Aim: The aim of this trial was to determine whether whole-body vibration (WBV) induced via a non-invasive oscillation platform could improve symptoms and health-related quality of life (HRQOL) in patients with chronic functional constipation. 2. Methods: A single-blinded, randomized, control trial was performed in a single Hospital in Taiwan. Patients diagnosed with chronic functional constipation, as per the Rome III diagnostic criteria were included and randomized to either the WBV treatment or no treatment (control) group. The treatment group received six 15-minute sessions of WBV therapy over a two-week period. Patients received vibrations of 2 mm in amplitude at a frequency of 12 Hz. The primary outcome was assessed by the constipation severity instrument (CSI). The secondary outcome was improvements in HRQOL.

Interventions

PROCEDUREwhole body vibration

to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance

Sponsors

Changhua Christian Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* met the Rome III criteria of constipation

Exclusion criteria

* pregnant * cardiovascular disease * cerebrovascular disease * recently undergone major surgery * hypothyroidism * depressive disorder.

Design outcomes

Primary

MeasureTime frame
change from baseline in constipation severity instrument (CSI) at 2 weeksbaseline (day 1), the completion of the trial (day 14)

Secondary

MeasureTime frame
change from baseline in health-related quality of life (HRQOL) at 2 weeksbaseline (day 1), the completion of the trial (day 14)

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026